SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Debt Conversion, Converted Instrument, Amount
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Debt Conversion, Converted Instrument, Amount of $9.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-12-31 was $450.47K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-09-30 was $0.00.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-06-30 was $68.25K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. debt conversion, converted instrument, amount for the quarter ending 2025-03-31 was $53.50K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. debt conversion, converted instrument, amount for fiscal 2025 was $572.22K.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.54M 10-Q · filed 2026-09-24 | |||
| 2025-12-31 | $450.47K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $450.47K derived: sum of 2 quarters · filed 2026-03-31 | $518.72K derived: sum of 3 quarters · filed 2026-03-31 | $572.22K 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $68.25K derived: sum of 2 quarters · filed 2025-11-13 | $121.75K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $68.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $121.75K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $53.50K 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |